=Kite Pharma (KITE) acquired by Gilead Sciences (GILD) for $180/share

Gilead Sciences (GILD) acquires Kite Pharma (KITE) for $180/share in cash, or approximately $11.9 bln. (8/28/17)

The deal will add the promising CAR-T candidate to Gilead's existing portfolio.
The acquisition was completed in October 2017.
In October 2017, Kite Pharma’s therapy, Yescarta (axicabtagene ciloleucel) became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

MIT Technology Review ranked Kite Pharma 7th in its annual list of 50 Smartest Companies 2017.